A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy

Author： Ramanathan Ramesh  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.30, Iss.4, 2012-08, pp. : 1591-1596

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer

By Advani Ranjana   Lum Bert   Fisher George   Halsey Joanne   Geary Richard   Holmlund Jon   Kwoh T.   Dorr F.   Sikic Branimir  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 467-477

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks

By Johnson Peter   Geldart Thomas   Fumoleau Pierre   Pinel Marie-Claire   Nguyen Laurent   Judson Ian  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 223-231

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies

By Chen Eric   Batist Gerald   Siu Lillian   Bangash Naeema   Maclean Martha   McIntosh Lynn   Miller Wilson   Oza Amit   Lathia Chetan   Petrenciuc Oana   Seymour Lesley  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 455-465

Springer Publishing Company

Access to resources Recommend Favorite

A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

By Gelmon K.   Hirte H.   Fisher B.   Walsh W.   Ptaszynski M.   Hamilton M.   Onetto N.   Eisenhauer E.  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 263-275

Springer Publishing Company

Access to resources Recommend Favorite

A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors

By Hilgers Werner   Faivre Sandrine   Chieze Stéphanie   Alexandre Jérôme   Lokiec François   Goldwasser François   Raymond Eric   Kahatt Carmen   Taamma Abdelkrim   Weems Garry   MacDonald John   Misset Jean-Louis   Cvitkovic Esteban  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 311-319

Springer Publishing Company

Access to resources Recommend Favorite